Japan Cardiac Surgery Instruments Market size was valued at USD 141.3 million in 2024 and is anticipated to surpass USD 357.1 million by the end of 2036, expanding at a CAGR of 8% during the forecast period, i.e., 2025-2036. In 2025, the industry size of japan cardiac surgery instruments is evaluated at USD 151.7 million.
The growth of Japan cardiac surgery instruments market is attributed to the increasing incidence of cardiovascular diseases, which is attributed to the growing geriatric population and altered lifestyle. Due to the population of 36 million people over 65 years, the need for sophisticated surgical treatment of cardiovascular diseases is rising in Japan. This trend drives competition and cooperation between medical device makers to create new products to support minimally invasive and robotic surgical procedures. In March 2024, Japan Lifeline signed an agreement with Meril Life Sciences to launch the Myval transcatheter heart valve in Japan, reflecting an increasing interest in minimally invasive heart procedures.
The government of Japan has been working closely to develop healthcare facilities to enhance the development of cardiac surgery. As stated by the Ministry of Health, Labour, and Welfare of Japan, medical device development and an increased number of cardiac centers are key drivers of japan cardiac surgery instruments market growth. Terumo Cardiovascular Systems, in July 2024, launched a USD 42 million manufacturing facility in Costa Rica to produce high-precision components for cardiopulmonary bypass systems for Japan and other regions. Such initiatives keep Japan at the forefront of cardiovascular treatment and enhance the country's healthcare industry.
Growth Drivers
Challenges
Base Year |
2024 |
Forecast Year |
2025-2036 |
CAGR |
8% |
Base Year Market Size (2024) |
USD 141.3 million |
Forecast Year Market Size (2036) |
USD 357.1 million |
Country Scope |
Japan (Tokyo, Yokohama, Osaka, Nagoya, Sapporo, Fukuoka, Kawasaki, Kobe, Kyoto and Saitama) |
Product Type (Forceps, Clamps, Scalpels, Scissors, Needle Holders, Others)
Forceps segment in the japan cardiac surgery instruments market is set to observe more than 8.4% growth through 2036. Forceps are commonly used by surgeons in the operating theatre for cardiac surgery for tissue manipulation, especially during bypass or valve surgery. In July 2024, Terumo Cardiovascular increased the production of advanced surgical forceps in the market segment, which strengthened its position. This has been due to the rising number of cardiac surgeries in Japan, especially among the elderly who need complicated procedures.
Application (Hospitals and Cardiac Centers/Clinics, Ambulatory Surgical Centers)
Hospitals and cardiac centers segment is set to capture japan cardiac surgery instruments market share of around 86.2% by the end of 2036. Consequently, specialized cardiac units that are fitted with a myriad of surgical tools and apparatus are of utmost importance in the growth of the market. In March of 2024, Japan Lifeline’s collaboration with Meril Life Sciences focused on the need to enhance the range of cardiac treatments in hospitals due to the increasing number of patients in need of valve replacement surgeries. This collaboration aims to streamline the distribution of advanced surgical instruments, ensuring faster access to life-saving technologies across key medical facilities.
Our in-depth analysis of the Japan cardiac surgery instruments market includes the following segments:
Product Type |
|
Application |
|
End use |
|
Tokyo Market Outlook
Tokyo is the largest healthcare in japan cardiac surgery instruments market due to the high population density that puts pressure on the healthcare delivery systems for cardiac surgery instruments. The city is endowed with some of the best health facilities in Japan and has put its money where its mouth is regarding the purchase of the latest surgical equipment and robotics to address the ever-growing need for cardiac procedures. In February 2024, DePuy Synthes launched its sternum fixation system in Tokyo hospitals to meet the increasing need for post-surgical products and enhance Tokyo’s reputation as a medical technology hub.
Osaka Market Outlook
Osaka is also anticipated to offer lucrative prospects to cardiac surgery instrument manufacturers in Japan due to the rising research funding and investment in medical device production. For example, the advanced cardiac center of Osaka University Hospital is continuously expanding the use of robotic surgical systems in surgeries. Terumo Corporation increased the company’s investment in extracorporeal circulation technology in July 2024 and made Osaka a center for advanced cardiac treatment in Japan.
The market for cardiac surgery instruments in Japan is highly competitive, and the key players are increasingly focusing on product innovation. The key players in the japan cardiac surgery instruments market are Terumo Corporation, Nipro, and Fukuda because they innovate new surgical devices for treating cardiovascular diseases. Other firms such as LivaNova and Medline Industries are dedicated to developing surgical solutions that help improve the efficiency and accuracy of cardiac surgeries.
In April 2024, Toyoda Gosei revealed new developments in its biopolymer-based cardiac implants to enhance heart valve replacement and restoration. This development is in line with the current trend of the japan cardiac surgery instruments market, which has moved towards bioengineered surgical solutions, which is in line with Japan’s long-term vision for its healthcare industry. Through innovation and the introduction of new products, market leaders are enhancing their market standings, thus guaranteeing continuous growth in the market.
Here are some leading companies in the Japan cardiac surgery instruments market:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?